Renal Cell Carcinoma News

This RSS feed URL is deprecated


This RSS feed URL is deprecated, please update. New URLs can be found in the footers at https://news.google.com/news

Optimizing Adjuvant Therapy in Renal Cell Carcinoma - OncLive



OncLive
 
Optimizing Adjuvant Therapy in Renal Cell Carcinoma 
OncLive
Adjuvant Sunitinib in High-Risk Renal-Cell Carcinoma after Nephrectomy [published online October 10, 2016]. N Engl J Med. doi: 10.1056/NEJMoa1611406. Hass NB, Manola J, Uzzo RG, et al. Adjuvant sunitinib or sorafenib for high-risk, non-metastatic renal ...

and more » 


Overexpression of CKAP4 Linked With Poor Prognosis in Renal Cell Carcinoma - Cancer Therapy Advisor



Cancer Therapy Advisor
 
Overexpression of CKAP4 Linked With Poor Prognosis in Renal Cell Carcinoma 
Cancer Therapy Advisor
Unlike with some other solid tumors, there are not many targetable mutations found in renal cell carcinoma (RCC). ?Having biomarkers for prognosis is important, but at the end of the day patients and physicians want to know what we can do differently ...

 


Dr. Agarwal on Remaining Questions With Renal Cell Carcinoma - OncLive



OncLive
 
Dr. Agarwal on Remaining Questions With Renal Cell Carcinoma 
OncLive
Neeraj Agarwal, MD, associate professor, Division of Oncology, Department of Medicine, University of Utah School of Medicine, Huntsman Cancer Institute, discusses remaining questions in renal cell carcinoma. Several new treatment combinations are being ...

and more » 


Expression of minichromosome maintenance genes in renal cell carcinoma - Dove Medical Press



Expression of minichromosome maintenance genes in renal cell carcinoma 
Dove Medical Press
Abstract: Minichromosome maintenance (MCM) proteins play an essential role in DNA replication. They have been shown to be overexpressed in various types of cancer. However, the role of this family in renal cell carcinoma (RCC) is widely unknown. In ...

 


Adjuvant Renal Cell Carcinoma Drug Receives FDA Greenlight - Specialty Pharmacy Times



Medscape
 
Adjuvant Renal Cell Carcinoma Drug Receives FDA Greenlight 
Specialty Pharmacy Times
?This is the first adjuvant treatment approved for patients with renal cell carcinoma, which is significant because patients with this disease who have a nephrectomy are often at high risk of the cancer returning,? said Richard Pazdur, MD, director of ...
FDA Approves Adjuvant Sunitinib for High-Risk RCC OncLive
FDA OKs First Adjuvant Treatment for Kidney Cancer Medscape
FDA Approves Sunitinib for Adjuvant Treatment of RCC Renal and Urology News
Healio 
all 10 news articles » 


SUO 2017: Sarcomatoid Differentiation in Renal Cell Carcinoma: Does Stage Make A Meaningful Difference On ... - UroToday



SUO 2017: Sarcomatoid Differentiation in Renal Cell Carcinoma: Does Stage Make A Meaningful Difference On ... 
UroToday
The authors queried the Memorial Sloan Kettering Cancer Center kidney cancer database of 3,850 patients with RCC who underwent partial or radical nephrectomy from 2000-2017. Patients were divided into four groups for the analysis: pT1-2NxMx RCC without ...

 


FDA Expands Sunitinib Indication To Include Adjuvant Therapy for Renal Cell Carcinoma - Cancer Therapy Advisor



Cancer Therapy Advisor
 
FDA Expands Sunitinib Indication To Include Adjuvant Therapy for Renal Cell Carcinoma 
Cancer Therapy Advisor
Thirty to 40% of patients with RCC relapse a median of 2 years after nephrectomy. The majority of relapses occur within 5 years. The US Food and Drug Administration (FDA) approved expanding the indication of sunitinib to include adjuvant therapy for ...
FDA Approves Sunitinib as Adjuvant for Renal Cell Carcinoma Pharmacy Practice News
Pfizer's Drug Approved As Adjuvant Treatment In Recurrent Renal Cell Carcinoma Pharmaceutical Processing
FDA Approves Sunitinib for Recurrent Renal Cell Carcinoma Cancer Network
FiercePharma  -Rare Disease Report  -PharmaTimes 
all 26 news articles » 


Adjuvant therapy in renal cell carcinoma: does higher risk for recurrence improve the chance for success? - UroToday



Adjuvant therapy in renal cell carcinoma: does higher risk for recurrence improve the chance for success? 
UroToday
The success of targeted therapies, including inhibitors of the vascular endothelial growth factor pathway or the mammalian target of rapamycin, in the treatment of metastatic renal cell carcinoma (RCC) led to interest in testing their efficacy in the ...

 


FDA approves adjuvant indication for Sutent in renal cell carcinoma - The Cancer Letter Publications



FDA approves adjuvant indication for Sutent in renal cell carcinoma 
The Cancer Letter Publications
?This is the first adjuvant treatment approved for patients with renal cell carcinoma, which is significant because patients with this disease who have a nephrectomy are often at high risk of the cancer returning,? said Richard Pazdur, director of the ...

 


ARMO BioSciences Presents Efficacy Data from its Phase 1b Trial in Patients with Metastatic Renal Cell Carcinoma at ... - PR Newswire (press release)



ARMO BioSciences Presents Efficacy Data from its Phase 1b Trial in Patients with Metastatic Renal Cell Carcinoma at ... 
PR Newswire (press release)
REDWOOD CITY, Calif., Dec. 8, 2017 /PRNewswire/ -- ARMO BioSciences, Inc., a late-stage immuno-oncology company, today announced additional clinical trial results on its lead investigational immuno-oncology drug AM0010 (pegilodecakin) in metastatic ...

and more »